Row 47390

Row ID: 47390 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 47390 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

Due to present their clinical updates towards the end of May at a conference. The CEO has stated he’s excited to show the progress and help people understand what the company has been working on. Now, if this were to be negative news it's highly likely he wouldn't wait to appear on stage to present it. It’s much more likely they would issue a Press Release prior to allow the news to settle.

Their cash hoard of $17b (Practically their entire market cap) is allowing them to essentially develop an expansive pipeline for <$500m/Yr net loss.   It's an extremely rare scenario for a Biotech name to be in.

It’s one of the healthiest balance sheets in the entire sector, period.

Barrons rightfully picked the name as a top pick for 2024, citing some of this data. It’s down 18% since then. With XBI moving, MRNA on a run and ample catalysts which could present themselves at any moment, this is a clear buy.

https://preview.redd.it/3nu6r37tgz1d1.png?width=840&format=png&auto=webp&s=f6fb631b927df33a3b49af2994b96c084af9aa9c

Weekly shows a clear bottom pattern followed by a tight 4 week range build below key MAs. Looking to position prior to a breakout whilst the price trades with a huge margin of safety.

FieldValue
text Due to present their clinical updates towards the end of May at a conference. The CEO has stated he’s excited to show the progress and help people understand what the company has been working on. Now, if this were to be negative news it's highly likely he wouldn't wait to appear on stage to present it. It’s much more likely they would issue a Press Release prior to allow the news to settle.   Their cash hoard of $17b (Practically their entire market cap) is allowing them to essentially develop…
label r/wallstreetbets
dataType post
communityName r/wallstreetbets
datetime 2024-05-22
username_encoded Z0FBQUFBQm5Lak1RMHpLeUxxYlZITWhIV3ZROUs3WDhxU2ZXZjdYelZGNWQ2cHRQUTh1Vk1GQ2xNc3djd2pVM2I0dEdtRVhfdU9FMXFYQkFwSFVyOVJPV1pxbHI1SHNjaWc9PQ==
url_encoded Z0FBQUFBQm5Lak9nT2Z6LW5LX191bVA4RlZvTkZvaEFGYThLOXRhWnphRDNBMzJ4bldoRjBfYml3TF9WM2ZWOG5wWWc0eV9WNk90MU1YTEVNR3VTQnBvSDZaNHktZU1aQkc3a09sX000RkxNcllHT2U3ci1hMUxzZE9nVnNpUG1LNXY3Q21LSUpTSHpKc3NoR0hBaWJXMldDbTF1M3NBTGVpb1EteVNHMVFkVjRZNFhnRG1IMFNETkhVT2lpbDdpekFKMWJvbUhrRXFJWDc0QlRLYlJ2djlxU3FKTmhadldiQT09

Raw Record

{
  "text": "Due to present their clinical updates towards the end of May at a conference. The CEO has stated he’s excited to show the progress and help people understand what the company has been working on. Now, if this were to be negative news it's highly likely he wouldn't wait to appear on stage to present it. It’s much more likely they would issue a Press Release prior to allow the news to settle.   \n\nTheir cash hoard of $17b (Practically their entire market cap) is allowing them to essentially develop an expansive pipeline for <$500m/Yr net loss.   It's an extremely rare scenario for a Biotech name to be in. \n\nIt’s one of the healthiest balance sheets in the entire sector, period.   \n\nBarrons rightfully picked the name as a top pick for 2024, citing some of this data. It’s down 18% since then. With XBI moving, MRNA on a run and ample catalysts which could present themselves at any moment, this is a clear buy.   \n\nhttps://preview.redd.it/3nu6r37tgz1d1.png?width=840&format=png&auto=webp&s=f6fb631b927df33a3b49af2994b96c084af9aa9c\n\nWeekly shows a clear bottom pattern followed by a tight 4 week range build below key MAs. Looking to position prior to a breakout whilst the price trades with a huge margin of safety.",
  "label": "r/wallstreetbets",
  "dataType": "post",
  "communityName": "r/wallstreetbets",
  "datetime": "2024-05-22",
  "username_encoded": "Z0FBQUFBQm5Lak1RMHpLeUxxYlZITWhIV3ZROUs3WDhxU2ZXZjdYelZGNWQ2cHRQUTh1Vk1GQ2xNc3djd2pVM2I0dEdtRVhfdU9FMXFYQkFwSFVyOVJPV1pxbHI1SHNjaWc9PQ==",
  "url_encoded": "Z0FBQUFBQm5Lak9nT2Z6LW5LX191bVA4RlZvTkZvaEFGYThLOXRhWnphRDNBMzJ4bldoRjBfYml3TF9WM2ZWOG5wWWc0eV9WNk90MU1YTEVNR3VTQnBvSDZaNHktZU1aQkc3a09sX000RkxNcllHT2U3ci1hMUxzZE9nVnNpUG1LNXY3Q21LSUpTSHpKc3NoR0hBaWJXMldDbTF1M3NBTGVpb1EteVNHMVFkVjRZNFhnRG1IMFNETkhVT2lpbDdpekFKMWJvbUhrRXFJWDc0QlRLYlJ2djlxU3FKTmhadldiQT09"
}
Explore Dataset Explore Row

Entry Information